ESTRO35 Programme Book

SATURDAY 30 APRIL 2016

SCIENTIFIC PROGRAMME

| PROGRAMME AND EXHIBITION GUIDE

14:30 > Do we need randomised clinical data to justify the use of SABR

for primary and oligometastatic cancer?

Speaker: F. Mcdonald (UK)

SP-0094

14:50 > Pre-clinical and clinical data on the radiobiological mechanism

for the efficacy of SABR

Speaker: M. Brown (USA)

SP-0095

15:10 > Technical developments in high precision radiotherapy: a new era

for clinical SABR trials?

Speaker: M. Aznar (Denmark)

SP-0096

15:30 > Radiation dose-volume effects for liver SBRT

M. Miften (USA), Y. Vinogradskiy, V. Moiseenko, J. Grimm, E. Yorke,

A. Jackson, W.A. Tomé, R. Ten Haken, N. Ohri, A.M. Romero,

K.A. Goodman, L.B. Marks, B. Kavanagh, L.A. Dawson

OC-0097

Symposium

TUMOUR TARGETING - CONSIDERING NORMAL TISSUE BIOLOGY

14:30 - 15:45 | LONDRA

Stem cells are thought to be major players in the response of normal tissue and tumours to (chemo-)

radiation. In this symposium recent developments in the field of (cancer) stem cell science and genetics

are combined. Using several techniques such as the stem cell culturing as organoids or basal cell lay-

ers derived from biopsies enabled the study the molecular cues involved in the (patient specific) treat-

ment response. Mathematical modelling of signalling network, (epi)genetic changes and response

analysis of specific stem/progenitor cells involving known and less well know cues are discussed in the

light of potential modification, optimisation and personalisation of radiotherapy.

Chair: R. Coppes (The Netherlands)

Co-chair: M. Mangoni (Italy)

14:30 > Organoids, a disease and patient specific in vitro model system

Speaker: R. Vries (The Netherlands)

SP-0098

14:48 > The role of ATM and p53 in normal tissue radiation response

Speaker: D. Kirsch (USA)

SP-0099

15:06 > Radiation sensitivity of human skin stem cells: dissecting epigenetic

effects of radiation

Speaker: M. Martin (France)

SP-0100

15:24 > A radiation systems biology view of radiation sensitivity of normal

and tumour cells

Speaker: K. Unger (Germany)

SP-0101